| 2026-06-04 07:00 | UU:INSM | | News Release200 | Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2026-05-27 07:00 | UU:INSM | | News Release200 | Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference |
| 2026-05-07 07:00 | UU:INSM | | News Release200 | Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-06 16:30 | UU:INSM | | News Release200 | Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis |
| 2026-05-04 07:00 | UU:INSM | | News Release200 | Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE(TM) Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026 |
| 2026-04-30 07:00 | UU:INSM | | News Release200 | Insmed to Present at May 2026 Investor Conferences |
| 2026-04-23 07:00 | UU:INSM | | News Release200 | Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 |
| 2026-04-07 16:01 | UU:INSM | | News Release200 | Insmed Provides Clinical Update on Phase 2b CEDAR Study |
| 2026-03-23 07:00 | UU:INSM | | News Release200 | Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE(TM) (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease |
| 2026-03-05 07:00 | UU:INSM | | News Release200 | Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2026-02-19 07:00 | UU:INSM | | News Release200 | Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update |
| 2026-02-13 07:00 | UU:INSM | | News Release200 | Insmed To Present at March 2026 Investor Conferences |
| 2026-02-05 07:00 | UU:INSM | | News Release200 | Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 |
| 2026-01-28 07:00 | UU:INSM | | News Release200 | Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress |
| 2026-01-09 07:00 | UU:INSM | | News Release200 | Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference |
| 2026-01-02 07:00 | UU:INSM | | News Release200 | Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-12-17 16:01 | UU:INSM | | News Release200 | Insmed Provides Clinical and Business Update |
| 2025-12-04 07:00 | UU:INSM | | News Release200 | Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2025-11-18 11:00 | UU:INSM | | News Release200 | European Commission Approves BRINSUPRI(TM) (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union |
| 2025-11-13 07:00 | UU:INSM | | News Release200 | Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good |
| 2025-11-05 07:00 | UU:INSM | | News Release200 | Insmed To Present at November and December 2025 Investor Conferences |
| 2025-10-30 07:00 | UU:INSM | | News Release200 | Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update |
| 2025-10-23 16:05 | UU:INSM | | News Release200 | Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List |
| 2025-10-17 07:00 | UU:INSM | | News Release200 | CHMP Recommends EU Approval of BRINSUPRI(TM) (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis |
| 2025-10-16 07:00 | UU:INSM | | News Release200 | Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 |
| 2025-10-15 07:00 | UU:INSM | | News Release200 | Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 |
| 2025-09-22 07:00 | UU:INSM | | News Release200 | Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025 |
| 2025-09-05 07:00 | UU:INSM | | News Release200 | Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2025-08-21 07:00 | UU:INSM | | News Release200 | Insmed To Present at September Investor Conferences |
| 2025-08-12 11:34 | UU:INSM | | News Release200 | FDA Approves BRINSUPRI(TM) (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease |
| 2025-08-07 07:00 | UU:INSM | | News Release200 | Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update |
| 2025-07-24 07:00 | UU:INSM | | News Release200 | Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 |